Mild cognitive impairment in older adults: Analysis of some factors

Maria Dos Anjos Dixe1, Mônica Braúna1, Timóteo Camacho1

  • 1Centre for Innovative Care and Health Technology (ciTechCare), Polytechnic Institute of Leiria (IPLeiria), Leiria, Portugal.

Insights

Mild cognitive impairment (MCI) affects many elderly individuals. Cognitive stimulation interventions should be tailored to residential settings, considering comorbidities and nutrition for better outcomes.

Area of Science:

  • Gerontology
  • Neuroscience
  • Public Health

Background:

  • Mild cognitive impairment (MCI) is a significant concern in aging populations, often linked to frailty.
  • Understanding the prevalence and correlates of MCI is crucial for developing targeted interventions.

Purpose of the Study:

  • To determine the prevalence of MCI in elderly individuals.
  • To examine sociodemographic and clinical factors associated with MCI.
  • To assess the relationship between MCI screening tools (6CIT) and detailed cognitive domains (MoCA).

Main Methods:

  • A correlational study involving 44 elderly individuals (average age 88.9 years) from day-care centers and care homes.
  • Data collection included structured interviews for sociodemographic and clinical information.

Main Results:

  • 63.6% of participants did not have MCI; no significant differences were found based on residential setting.
  • Individuals living at home showed higher BMI and more pathologies than institutionalized residents.
  • The 6-item Cognitive Impairment Test (6CIT) and Montreal Cognitive Assessment (MoCA) showed discrepancies in general cognitive function and specific domains (visual, attention, abstraction, orientation).

Conclusions:

  • Cognitive stimulation strategies need to be adapted based on the individual's residential environment, considering comorbidities and nutritional status.
  • Further research is needed to refine MCI assessment tools and interventions for diverse elderly populations.

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
688
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
456
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
141
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
454
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
168